Your Search Returned 52 tagged news reports
They're both looking for objects of great value, and the vast majority of their attempts to find them fail. Ben Cravatt and colleagues from The Scripps Research Institute have been devising an improved tool kit to find the treasures they seek:
The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia...Cloud Pharmaceuticals, a
The team, led by Chi Li, Ph.D., assistant professor of medicine, published its finding in the April 2014 issue of Molecular and Cellular Biology. One of the characteristics of lung cancer is the dysregulation of apoptosis, or regulated cell death...
I wanted to run it past a wider audience to see if I'm grounded in reality, or out on my own island (which has happened before). Without getting into any details, we were talking about an area of potential drug research that has to do with
Special Arrangement The team targeted a class of proteins never before studied anywhere in the world in any bacteria as antimicrobial agents...The proof-of-concept study opens up new approaches to intervention; but better molecules are needed to take
The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases. Under the terms of the agreement, X-Chem is applying its discovery engine, which leverages a high diversity,
Here's a review of protein-protein interaction "hot spots" and their application to drug discovery...This one doesn't break much new ground, but it does provide a number of recent examples, all in one place. People approach this subject because of
Modulators belonging to the patented class have been shown to be necessary for the high-throughput derivation of transgene-free hiPSCs, and for the maintenance, survival and genomic stability of hiPSCs in culture...PSCs for therapeutic applications. "
Over at LifeSciVC , guest blogger Jonathan Montagu talks about small molecules in drug discovery, and how we might move beyond them...Well worth a read, even if he's more sanguine about structure-based drug discovery than I am...These things need the
UCB's research arm UCB NewMedicines has used a new approach to identify small molecules modulators of a biological pathway, for which parenterally administered biologic therapies have proven highly efficacious in patients. The deal will see formation